BeOne Medicines (BEIGF) Equity Income (2020 - 2023)

BeOne Medicines (BEIGF) has reported Equity Income for 4 consecutive years, with -$3.9 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Equity Income rose 29.29% year-over-year to -$3.9 million in Q4 2023; TTM through Dec 2023 was -$9.3 million, a 70.49% increase from a year earlier, with the FY2023 full-year figure at -$16.2 million, up 26.25% from the prior year.
• Equity Income was -$3.9 million for Q4 2023 at BeOne Medicines, down from -$2.7 million in the prior quarter.
• Over five years, Equity Income peaked at $23.8 million in Q3 2021 and troughed at -$17.0 million in Q1 2022.
• A 4-year average of -$1.3 million and a median of -$2.6 million in 2023 frame the typical range for Equity Income.
• The widest YoY moves for Equity Income: up 2367.56% in 2021, down 614.79% in 2021.
• Over 4 years, Equity Income stood at $1.9 million in 2020, then slumped by 614.79% to -$9.5 million in 2021, then surged by 41.44% to -$5.6 million in 2022, then rose by 29.29% to -$3.9 million in 2023.
• The last three Equity Income figures came in at -$3.9 million (Q4 2023), -$2.7 million (Q3 2023), and -$2.5 million (Q2 2023), per Business Quant data.